Saros Therapeutics is working to enhance patients' response to immunotherapy by harnessing the STING pathway with a strategy to overcome the limitations of prior STING agonists.  In combination with existing immunotherapies, this approach has the potential to enable a safe and more effective immune response against the tumor than with immunotherapy alone.

Biotechnology

Life Sciences

Pharmaceutical

Therapeutics

Saros Therapeutics

Saros Therapeutics' headquarters in Chicago, United States

Description

People (3)

Matt Martin

Richard Johnson

Yu Leo Lei

Jobs